Highest-materiality recent filing
Acrivon Q1 net loss $19.0M; cash $97.7M; key ACR-368 interim readout in H2 2026
Net loss $19.0M vs $19.7M YoY; R&D $15.2M, G&A $4.7M.
Acrivon Therapeutics Q4/FY2025 net loss $19M/$77.9M; cash $118.6M; ACR-368 52% cORR in serous EC
Net loss Q4 $19.0M, FY $77.9M; cash and securities $118.6M expected to fund into Q2 2027.
Acrivon terminates Akoya/Quanterix diagnostic deal; opens internal CLIA lab
Mutually terminated OncoSignature Companion Diagnostic Agreement with Akoya (Quanterix) effective Feb 25, 2026.
Interim data from ACR-368 Phase 2b registrational-intent trial presented at ESGO Congress on February 27, 2026.
ACR-368 Phase 2b: 39% ORR overall; in serous EC ≤2 prior lines, cORR 52% (N=23) and 67% in BM+ (N=12). Arm 3 expanding to EU, enrollment complete Q4 2026.
Acrivon Therapeutics Provides Clinical Data Updates for ACR-368 and Initial ACR-2316 Data
On January 8, 2026, Acrivon hosted a webcast and conference call featuring ACR-368 clinical data and program updates.
Syngeneic mouse model: sustained complete tumor regression and immune memory after multiple implant rounds over ~1 year.
Acrivon's ACR-368 shows 35% cORR in endometrial cancer; cash $164.8M
Q1 2025 net loss $19.7M vs $16.5M YoY; R&D spend $15.4M on trial advancement.
Acrivon Therapeutics appoints Mansoor Raza Mirza as CMO effective April 9, 2025
Dr. Mirza is a gynecologic oncology KOL who led registrational trials for Zejula (PARP inhibitor) and frontline endometrial cancer therapy.
Acrivon reports Q4/FY24 net loss $22.8M/$80.6M; ACR-368 endometrial cancer cORR 35% in BM+ patients
Cash $184.6M as of Dec 31, 2024; runway extended into 2027.
Acrivon reports ACR-368 35% ORR in refractory endometrial cancer; deprioritizes ovarian/bladder
Preliminary cash, cash equivalents and ST investments ~$184.6M as of Dec 31, 2024; runway into 2027.
Acrivon appoints Adam Levy as CFO; Rasmus Holm-Jorgensen steps down effective April 1, 2025
Rasmus Holm-Jorgensen resigns as CFO effective April 1, 2025, for personal reasons to pursue Europe-based opportunity; no disagreement.
Acrivon reports Q3 net loss $22.4M; ACR-368 shows 62.5% ORR in endometrial cancer
Net loss Q3 2024: $22.4M vs $14.5M in Q3 2023; R&D expenses rose to $18.9M from $10.3M.
Acrivon doses first patient in Phase 1 trial of WEE1/PKMYT1 inhibitor ACR-2316
First patient dosed two quarters ahead of original timeline for ACR-2316 Phase 1 trial in solid tumors.
ACR-368 endometrial cancer Phase 2: 62.5% ORR in OncoSignature+ patients; ACR-2316 IND cleared
Confirmed ORR of 62.5% (95% CI 30.4-86.5) in prospectively-selected OncoSignature+ endometrial cancer patients who progressed on anti-PD-1.
Acrivon Q2 net loss $18.8M; $220.4M cash; ACR-368 Phase 2 shows 50% ORR
Net loss of $18.8M vs $13.9M YoY; R&D expenses $15.0M, G&A $6.4M.
Acrivon Q1 net loss $16.5M; ACR-368 Phase 2b 50% ORR; $130M PIPE
Net loss $16.5M vs $12.8M YoY; R&D $11.5M, G&A $6.2M.
Phase 2b: 50% confirmed ORR in OncoSignature-positive ovarian/endometrial (10 pts), 0% ORR in negative (16), p=0.0038.
Acrivon nets ~$130M in PIPE; shares at $8.50, pre-funded warrants for 7.1M shares
Gross proceeds ~$130M from 8.235M shares at $8.50/share and 7.06M pre-funded warrants at $8.499/warrant.
On March 11, 2025, Rasmus Holm-Jorgensen, the Company’s Chief Financial Officer, notified the Company of his decision to step down from his position, effective April 1, 2025, for personal reasons to pursue another opportunity with a company based in Europe, allowing him to spend more time near his family.
On March 14, 2025, Acrivon Therapeutics, Inc. (the “Company”) appointed Adam Levy, Ph.D., M.B.A., to the position of Chief Financial Officer, effective as of April 1, 2025 (the “Effective Date”).
Max materiality 0.85 · Median 0.65 · Most common event other_material